The main purpose of this study is to learn if GB0139 works and how safe GB0139 is compared to placebo.
To find out if this trial is suitable for you please register below, or contact our Clinical Trials Team at email@example.com or phone 6151 0888.
Eligibility & Requirements
- Aged 40 years and older
- Diagnosis of idiopathic pulmonary fibrosis (IPF) in the last three years
- The phase 2 clinical trial will run for up to 116 weeks.
- During this period you will be required to attend up to 10 visits to the Institute for Respiratory Health at Level 2, 6 Verdun Street, Nedlands WA 6009.
Sign up today
Bayesian Evidence-Adaptive Treatment in Cystic Fibrosis (BEAT CF)